Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
SALARYThe position offers a permanent employment contract under the Italian National Collective Bargaining Agreement (CCNL) for the Commerce sector. The job level will be aligned with the candidate’s seniority, and the gross annual base salary will